AFP and hepatocellular carcinoma: Collectively, these findings highlight week 3 as the key time point for identifying primary progression and week 9 as the optimal landmark for predicting early progression, supporting the clinical utility of dynamic AFP and DCP monitoring as a non-invasive and practical biomarker-guided strategy for treatment optimization in unresectable HCC.